These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12207129)

  • 1. Intravitreal penetration of cefepime after systemic administration to humans.
    Aras C; Ozdamar A; Ozturk R; Karacorlu M; Ozkan S
    Ophthalmologica; 2002; 216(4):261-4. PubMed ID: 12207129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular penetration of cefepime following systemic administration in humans.
    Ozdamar A; Aras C; Ozturk R; Karacorlu M; Bahcecioglu H; Ozkan S
    Ophthalmic Surg Lasers; 2001; 32(1):25-9. PubMed ID: 11195739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous.
    Hariprasad SM; Blinder KJ; Shah GK; Apte RS; Rosenblatt B; Holekamp NM; Thomas MA; Mieler WF; Chi J; Prince RA
    Arch Ophthalmol; 2005 Jan; 123(1):39-44. PubMed ID: 15642810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitreous penetration of orally administered gatifloxacin in humans.
    Hariprasad SM; Mieler WF; Holz ER
    Trans Am Ophthalmol Soc; 2002; 100():153-9. PubMed ID: 12545689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penetration of piperacillin into the vitreous after intravenous administration.
    Robinet A; Le Bot MA; Colin J; Riche C
    Retina; 1998; 18(6):526-30. PubMed ID: 9869461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitreous and aqueous penetration of orally administered gatifloxacin in humans.
    Hariprasad SM; Mieler WF; Holz ER
    Arch Ophthalmol; 2003 Mar; 121(3):345-50. PubMed ID: 12617704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.
    Burgess DS; Hastings RW; Hardin TC
    Clin Ther; 2000 Jan; 22(1):66-75. PubMed ID: 10688391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection.
    Inoue M; Takeda K; Morita K; Yamada M; Tanigawara Y; Oguchi Y
    Am J Ophthalmol; 2004 Dec; 138(6):1046-8. PubMed ID: 15629301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
    Vedantham V; Lalitha P; Velpandian T; Ghose S; Mahalakshmi R; Ramasamy K
    Eye (Lond); 2006 Nov; 20(11):1273-8. PubMed ID: 16200061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration.
    Fiscella RG; Lai WW; Buerk B; Khan M; Rodvold KA; Pulido JS; Labib S; Shapiro MJ; Blair NP
    Ophthalmology; 2004 Jun; 111(6):1191-5. PubMed ID: 15177970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aqueous and vitreous penetration of levofloxacin after oral administration.
    Fiscella RG; Nguyen TK; Cwik MJ; Phillpotts BA; Friedlander SM; Alter DC; Shapiro MJ; Blair NP; Gieser JP
    Ophthalmology; 1999 Dec; 106(12):2286-90. PubMed ID: 10599658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy.
    Lai WW; Chu KO; Chan KP; Choy KW; Wang CC; Tsang CW; Pang CP
    Am J Ophthalmol; 2007 Aug; 144(2):315-8. PubMed ID: 17659971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia.
    Jaruratanasirikul S; Sriwiriyajan S; Ingviya N
    J Pharm Pharmacol; 2002 Dec; 54(12):1693-6. PubMed ID: 12542901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study.
    Descombes E; Martins F; Hemett OM; Erard V; Chuard C
    BMC Pharmacol Toxicol; 2016 Feb; 17():4. PubMed ID: 26846675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitreous penetration of orally administered famciclovir.
    Chong DY; Johnson MW; Huynh TH; Hall EF; Comer GM; Fish DN
    Am J Ophthalmol; 2009 Jul; 148(1):38-42.e1. PubMed ID: 19375688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of newer cephalosporins after subconjunctival and intravitreal injection in rabbits.
    Barza M; Lynch E; Baum JL
    Arch Ophthalmol; 1993 Jan; 111(1):121-5. PubMed ID: 8424709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
    Hariprasad SM; Shah GK; Mieler WF; Feiner L; Blinder KJ; Holekamp NM; Gao H; Prince RA
    Arch Ophthalmol; 2006 Feb; 124(2):178-82. PubMed ID: 16476886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of pharmacokinetic consultation of cefepime treatment for Pseudomonas aeruginosa bacteremia: a case report of severe thermal burn injury.
    Aoki Y; Urakami T; Magarifuchi H; Nagasawa Z; Nagata M; Fukuoka M
    J Infect Chemother; 2011 Jun; 17(3):407-11. PubMed ID: 20922450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.